Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07791615 Stapokibart Extranodal NK-T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07791615 Stapokibart Extranodal NK-T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791615 clinical trial report covering Stapokibart, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07796113 Adebrelimab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07796113 Adebrelimab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07796113 clinical trial report covering Adebrelimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07791498 Teclistamab Waldenstrom's macroglobulinaemia refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07791498 Teclistamab Waldenstrom's macroglobulinaemia refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791498 clinical trial report covering Teclistamab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07795749 Paclitaxel Adenocarcinoma of large intestine Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07795749 Paclitaxel Adenocarcinoma of large intestine Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795749 clinical trial report covering Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600131184 Thymalfasin Node-positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600131184 Thymalfasin Node-positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
ChiCTR2600131184 clinical trial report covering Thymalfasin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07796126 Albumin-Bound Paclitaxel Squamous Cell Carcinoma of Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07796126 Albumin-Bound Paclitaxel Squamous Cell Carcinoma of Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07796126 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07795814 EDG-15400 Heart failure with normal ejection fraction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07795814 EDG-15400 Heart failure with normal ejection fraction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795814 clinical trial report covering EDG-15400, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07794488 Recombinant Human Endostatin (Simcere) Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07794488 Recombinant Human Endostatin (Simcere) Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794488 clinical trial report covering Recombinant Human Endostatin (Simcere), Phase 2, endpoints, sponsor, geography, readout timing and development w
Read →
NCT07795424 Trastuzumab Hormone receptor positive HER2 positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07795424 Trastuzumab Hormone receptor positive HER2 positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795424 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07793942 Epinephrine Bitartrate Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07793942 Epinephrine Bitartrate Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07793942 clinical trial report covering Epinephrine Bitartrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07770984 Ombitasvir/Paritaprevir/Ritonavir Hepatitis C Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07770984 Ombitasvir/Paritaprevir/Ritonavir Hepatitis C Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07770984 clinical trial report covering Ombitasvir/Paritaprevir/Ritonavir, Phase 2/3, endpoints, sponsor, geography, readout timing and development whit
Read →
NCT07795177 Rezvilutamide Hormone-dependent prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07795177 Rezvilutamide Hormone-dependent prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795177 clinical trial report covering Rezvilutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →